GEHC Shorts Cover as Earnings Beat Resets the Story

GE HealthCare Technologies delivered a sharp post-earnings reset last week, with shorts who had rebuilt aggressively into the October 30 print now covering and analysts racing to lift targets above where the stock currently trades.

The short interest unwind is the clearest consequence of the beat. Bears had pushed positions from around 16.6 million shares in early October to a peak of 21.2 million on October 23, a 28% build in a fortnight documented in the two previous ORTEX notes on this name. Since that peak, shorts have covered steadily, with the ORTEX daily estimate back to 18.9 million shares, or 4.1% of the free float, a 6% reduction on the week. The ORTEX short score has retreated from 45.8 on October 23 to 42.6 now, consistent with the tactical nature of those positions rather than a structural short thesis. Borrow conditions remain loose: cost to borrow is 0.47%, up 22% on the week but still well within the low category, and availability is an ample 1,403% of outstanding short interest, meaning the lending pool has far more capacity than shorts are using. None of the borrow mechanics point to squeeze pressure.

Options positioning has tilted more bullish than usual. The put/call ratio has dropped to 0.63, below its 20-day average of 0.67 and roughly one standard deviation below that mean. That is not an extreme reading, but the direction is notable: where options traders were running a more neutral stance heading into earnings, they have since rotated toward calls. The 52-week PCR range runs from 0.48 to 2.22, so there is room for further call-side building without reaching anything unusual.

The Street moved sharply in the same direction. Within 24 hours of the print, JP Morgan raised its target from $70 to $80 (Neutral), Citigroup went from $71 to $79 (Neutral), RBC lifted to $90 from $80 (Outperform), and Barclays moved to $95 from $85 (Overweight). All four maintained existing ratings, so this is a valuation re-anchoring rather than a conviction shift. The consensus mean now stands at $86.80 against a Friday close of $76.57, leaving roughly 13% implied upside. Bulls point to a $23.9 billion backlog, a half-recurring revenue model spanning imaging, diagnostics and digital, and management's 17-20%+ operating margin target, supported by the Sofie Biosciences radiopharmaceuticals acquisition. Bears focus on low-single-digit revenue growth assumptions, China exposure that has fallen from 15% of revenue in 2021 to 11% in 2025, and $250 million of tariff impact absorbed in 2025. The analyst recommendation divergence factor ranks in the 94th percentile of the ORTEX universe, a signal that active managers are more split on this name than the consensus target alone suggests.

Valuation has re-rated with the stock. The price/earnings multiple has expanded by 2.0 turns over the past 30 days to 14.2x, and price/book is up 0.39x over the same period to 2.44x. EV/EBITDA at 9.8x has been broadly stable. The earnings yield ranks in the 80th percentile and the EV/EBIT factor in the 72nd, suggesting the market is giving credit for earnings quality even if the headline multiples have moved up. The ORTEX buyback data adds a further support layer: shares repurchased in Q2 2026 were up 136% on the prior year at 3.3 million shares, with spend doubling to $200 million, a sign management was active in buying back stock at lower prices.

Among peers, the contrast this week is stark. STE fell 2.2%, BDX slipped 0.5%, and BAX dropped 9.1%. GEHC gained 7.2% on the week, making the earnings-driven divergence the dominant feature of the peer group rather than any sector-wide move.

The next earnings print is scheduled for February 5, 2027, leaving 95 days for the Street to decide whether the target upgrades reflect a durable re-rating or simply catch-up after a period of misaligned targets. The pace of short covering from the 21.2 million peak, and whether the call-side options interest builds further, are the positioning metrics worth tracking into year-end.